Results 131 to 140 of about 97,509 (188)

De novo design of bioactive phenol and chromone derivatives for inhibitors of Spike glycoprotein of SARS-CoV-2 in silico. [PDF]

open access: yes3 Biotech, 2023
Lima JPO   +9 more
europepmc   +1 more source

Identification of an Unnatural Sulfated Monosaccharide as a High-Affinity Ligand for Pan-Variant Targeting of SARS-CoV-2 Spike Glycoprotein. [PDF]

open access: yesACS Chem Biol
Thompson A   +8 more
europepmc   +1 more source

CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy. [PDF]

open access: yesJ Med Virol, 2023
Machado TL   +12 more
europepmc   +1 more source

Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learning. [PDF]

open access: yesPLoS Comput Biol
Ferraz MVF   +9 more
europepmc   +1 more source

Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. [PDF]

open access: yesImmunity, 2023
Liu L   +19 more
europepmc   +1 more source

Bottom-up Assembled Synthetic SARS-CoV-2 Miniviruses Reveal Lipid Membrane Affinity of Omicron Variant Spike Glycoprotein. [PDF]

open access: yesACS Nano, 2023
Yagüe Relimpio A   +7 more
europepmc   +1 more source

Ebola Virus Spike Glycoprotein Recruits Cholesterol for Efficient Fusion [PDF]

open access: yesBiophysical Journal, 2018
Jinwoo Lee   +7 more
openaire   +1 more source

Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV. [PDF]

open access: yesJ Clin Invest
Suryadevara N   +12 more
europepmc   +1 more source

Association of Clinical Features with Spike Glycoprotein Mutations in Iranian COVID-19 Patients. [PDF]

open access: yesJ Clin Med, 2022
Ahangarzadeh S   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy